Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sunil Patel Insider Profile
4 Followers
Sunil Patel, EVP and CFO at OncoMed Pharma, holds 224.26K shares in OmniAb (Ticker: OABI), holds 28.82K shares in Ligand Pharma (Ticker: LGND), holds 17.84K shares in OncoMed Pharma (Ticker: OMED).
Profitable Transactions
8 out of 9 Profitable Transactions
Average Return
+47.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Sunil Patel
Sunil Patel's Trading History
OncoMed Pharma
Oct 12, 2017
―
Informative Sell
5.29K
$15.88K
OmniAb
Feb 01, 2023
Director
Uninformative Buy
―
$1.02M
Ligand Pharma
Nov 03, 2022
Former Director
Uninformative Sell
―
$2.06M
List of latest transactions for each holding click on a transaction to see Sunil Patel's performance on stock
You May Also Like
Sunil Patel insider profile FAQ
What is the percentage of profitable transactions made by Sunil Patel?
The percentage of profitable transactions made by Sunil Patel is 89%.
What is the average return per transaction made by Sunil Patel?
The average return per transaction made by Sunil Patel is 47.30%.
What stocks does Sunil Patel hold?
Sunil Patel holds: OMED, OABI, LGND stocks.
What was Sunil Patel’s latest transaction?
Sunil Patel latest transaction was an Uninformative Buy of ―.
What was Sunil Patel's most profitable transaction?
Sunil Patel’s most profitable transaction was an Informative Buy of LGND stock on November 4, 2020. The return on the trade was 79.80%.
What is Sunil Patel's role in OncoMed Pharma?
Sunil Patel's role in OncoMed Pharma is EVP and CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.